Patient characteristics for subjects with immune response assessed by 7-plex immunohistochemistry and multispectral imaging and the remaining subjects in the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer substudy
| Parameter | Total (N=336) | Immune response assessed (n=66) | Immune response not assessed (n=270) | P value |
| Age (years), median (IQR) | 50 (43–61) | 49 (42–58) | 51 (43–61) | 0.396 |
| Age group (years), n (%) | ||||
| <40 | 59 | 12 (18.2) | 47 (17.4) | |
| 40–50 | 94 | 21 (31.8) | 73 (27.0) | |
| 50–60 | 90 | 18 (27.3) | 72 (26.7) | |
| >60 | 92 | 14 (21.2) | 78 (28.9) | |
| Missing | 1 | 1 (1.5) | 0 (0) | |
| Menopausal status, n (%) | ||||
| Premenopausal | 163 | 36 (54.5) | 127 (47.0) | 0.187 |
| Postmenopausal | 157 | 25 (37.9) | 132 (48.9) | |
| Missing | 16 | 5 (7.6) | 11 (4.1) | |
| Histological subtype, n (%) | ||||
| No special type, ductal | 304 | 60 (90.9) | 244 (90.4) | 0.999 |
| Invasive lobular | 7 | 1 (1.5) | 6 (2.2) | |
| Medullary | 9 | 2 (3.0) | 7 (2.6) | |
| Other | 12 | 2 (3.0) | 10 (3.7) | |
| Missing | 4 | 1 (1.5) | 3 (1.1) | |
| PAM50 subtype, n (%) | ||||
| Basal | 250 | 57 (86.4) | 193 (71.5) | 0.487 |
| HER2 | 19 | 2 (3.0) | 17 (6.3) | |
| LumA | 5 | 0 (0) | 5 (1.9) | |
| Normal | 26 | 6 (9.1) | 20 (7.4) | |
| Missing | 36 | 1 (1.5) | 35 (13.0) | |
| Clinical tumor stage, n (%) | ||||
| 1 | 125 | 20 (30.3) | 105 (38.9) | 0.353 |
| 2 | 188 | 43 (65.2) | 145 (53.7) | |
| 3 | 18 | 2 (3.0) | 16 (5.9) | |
| 4 | 5 | 1 (1.5) | 4 (1.5) | |
| Clinical nodal status, n (%) | ||||
| 0 | 248 | 51 (77.3) | 197 (73.0) | 0.854 |
| 1 | 77 | 13 (19.7) | 64 (23.7) | |
| 2–3 | 11 | 2 (3.0) | 9 (3.3) | |
| Treatment, n (%) | ||||
| nab-paclitaxel+gemcitabine | 182 | 40 (60.6) | 142 (52.6) | 0.242 |
| nab-paclitaxel+carboplatin | 154 | 26 (39.4) | 128 (47.4) | |
| pCR, n (%) | ||||
| No | 206 | 42 (63.6) | 164 (60.7) | 0.992 |
| Yes | 118 | 24 (36.4) | 94 (34.8) | |
| Missing | 12 | 0 (0) | 12 (4.4) | |
| Ki-67, median (IQR) | 72.5 (50–80) | 75 (60–90) | 70 (50–80) | 0.152 |
| Missing | 12 | 0 | 12 | |
| Early response, n (%) | ||||
| No | 118 | 37 (56.9) | 81 (41.1) | 0.026* |
| Yes | 144 | 28 (43.1) | 116 (58.9) | |
| Missing | 74 | 1 (1.5) | 73 (27.0) |
*Among patients with evaluable pCR.
pCR, pathological complete response.